Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy

Liver Transplantation

Volumn 17, Issue 11, 2011, Pages 1344-1354

  Cucchetti, Alessandro ^a   Cescon, Matteo ^a   Bigonzi, Eleonora ^a   Piscaglia, Fabio ^b   Golfieri, Rita ^b   Ercolani, Giorgio ^a   Morelli, Maria Cristina ^a   Ravaioli, Matteo ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; DEATH; DISEASE SEVERITY; END STAGE LIVER DISEASE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PATIENT DROPOUTS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WAITING LISTS; YOUNG ADULT;

EID: 82955165182     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22397     Document Type: Article

References (31)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
2. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadl-mann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13:272-279. (Pubitemid 46351654)
3. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909. (Pubitemid 39425785)
4. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-967. (Pubitemid 40250844)
5. Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008;8:1177-1185. (Pubitemid 351763682)
6. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpen-zano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011;53: 1580-1589.
7. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278.
8. De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, et al. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl 2010;16:503-512.
9. Vitale A, D'Amico F, Frigo AC, Grigoletto F, Brolese A, Zanus G, et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010;17:2290-2302.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; for EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepa-tol 2001;35:421-430. (Pubitemid 32844200)
11. Bruix J, Sherman M; for Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepato-logy 2005;42:1208-1236. (Pubitemid 43112690)
12. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8:2547-2557.
13. United Network for Organ Sharing. Policy 3.6.4.4. Liver transplant candidates with hepatocellular carcinoma (HCC). http://optn.transplant.hrsa.gov/ PoliciesandBylaws2/policies/pdfs/policy-8.pdf. Accessed July 2011.
14. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
17. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-623.
18. Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, et al. A new priority policy for patients with he-patocellular carcinoma awaiting liver transplantation within the Model for End-Stage Liver Disease system. Liver Transpl 2007;13:857-866. (Pubitemid 46947850)
19. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006;6:1416-1421. (Pubitemid 44030324)
20. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
21. Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995;76:579-588.
22. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536. (Pubitemid 34260532)
23. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004;91:1229-1235. (Pubitemid 39424779)
24. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
25. Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, et al.; for Liver Match Investigators. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011;43:155-164.
26. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-4694.
27. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011;140:1618-1628.
28. Cucchetti A, Vitale A, Gaudio MD, Ravaioli M, Ercolani G, Cescon M, et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010;10:619-627.
29. Kim WR, Therneau TM, Benson JT, Kremers WK, Rosen CB, Gores GJ, Dickson ER. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology 2006;43:345-351.
30. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12: 1260-1267. (Pubitemid 44194595)
31. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004;78:1780-1786. (Pubitemid 40041645)